{"id":"W2193716145","doi":"10.1016/s1470-2045(15)00464-7","title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":849,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"Cilag; Onyx Pharmaceuticals; Amgen; Takeda Oncology; Spectrum Pharmaceuticals; Array BioPharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Chugai Pharmaceutical","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Refractory (planetary science); Population; Tolerability; Interim analysis; Oncology; Surgery; Clinical trial; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1799697924150374,"score_gpt":0.430217007053223,"score_spread":0.2502472146381857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}